NCT01134120已完成1 期
A Phase 1 Study of LY2784544 in Patients With JAK2 V617F-Positive Myeloproliferative Disorders
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Determination of a recommended Phase 2 dosing regimen
研究概览
简要总结
The purpose of this study is to find out the safe dose range of the study drug in patients with myeloproliferative disorders.
详细描述
The purpose of the study is to learn:
- How much and how often LY2784544 should be given to patients
- What is the safety profile of LY2784544 and any side effects that might be associated with it
- How LY2784544 is taken up, distributed, broken down, and passed out of your body
- Whether LY2784544 can help patients with myeloproliferative disorders
- If any markers in the blood (biomarkers) can identify patients who will respond better to the study drug.
The planned duration of the study is not fixed. The length of time patients participate in the study will be determined by the investigator/study doctor.
Part A of the study is to determine the dose of the study drug. Part A is divided into two sections, A1 and A2. In Part A1, patients will be given study drug without a lead-in period. In Parts A2 and B, patients will have a lead-in period of 2 or 4 weeks with a low dose of LY2784544 prior to taking a higher dose of LY2784544. Part B of the study is to confirm the safety of the dose and schedule.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have a diagnosis of polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF) as defined by the World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms and meet the following additional sub-type specific criteria:
- •A. PV: has failed or is intolerant of standard therapies or refuses to take standard medications
- •B. ET: has failed or is intolerant of standard therapies or refuses to take standard medications
- •C. MF (patients with MF must meet at least one of the following):
- •i. has intermediate or high-risk MF according to the Lille scoring system; or
- •ii. has symptomatic MF with spleen greater than 10 cm below left costal margin; or
- •iii. has post-polycythemic MF; or
- •iv. has post-ET MF
- •Have a quantifiable JAK2 V617F mutation
- •Have discontinued all previous approved therapies for myeloproliferative disorders, including any chemotherapy, immunomodulating therapy (for example, thalidomide, interferon-alpha), immunosuppressive therapy (for example, corticosteroids greater than 10 mg/day prednisone or equivalent), radiotherapy, and erythropoietin, thrombopoietin, or granulocyte colony stimulating factor for at least 14 days and recovered from the acute effects of therapy. Hydroxyurea used to control blood cell counts is permitted at study entry if the subject has been maintained on a stable dose for at least 4 weeks. Low-dose acetylsalicylic acid (aspirin) is permitted as well
排除标准
- •Have received treatment within 14 days of the initial dose of study drug with an experimental agent that has not received regulatory approval for any indication
- •Are currently being treated with agents that are metabolized by CYP3A4 with a narrow therapeutic margin (for example, alfentanil, cyclosporine, diergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus) or CYP2B6 (for example, cyclophosphamide, ifosfamide, tamoxifen, efavirenz, propofol, methadone, and bupropion)
- •Are currently being treated with warfarin or one of its derivatives which is known to alter levels of protein C or protein S. An exception to this criterion will be allowed for patients with a prior history of Budd-Chiari Syndrome who are being treated with warfarin or one of its derivatives
研究组 & 干预措施
LY2784544
Experimental
干预措施: LY2784544 (Drug)
结局指标
主要结局
Determination of a recommended Phase 2 dosing regimen
时间窗: Time of first dose until last dose
Number of participants with clinical significant effects
时间窗: Time of first dose until last dose
次要结局
- Preliminary pharmacokinetics of LY2784544 (Cmax)(Part A1: Day 1,2,15, and 29; Part A2: Day 7, 14, 21, 28, 29, 56, and 57; Part B: Day 1, 29, 57, and 113)
- Preliminary pharmacokinetics of LY2784544 (AUC)(Part A1: Day 1,2,15, and 29; Part A2: Day 7, 14, 21, 28, 29, 56, and 57; Part B: Day 1, 29, 57, and 113)
- Malignant clone burden(Part A1: Baseline (2 times), Weeks 13, 21 and every 6 months while patient is on study; Parts A2 and B: Baseline (2 times), Weeks 5, 8, 17, 25 and every 6 months while patient is on study)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
A Phase 1 Study of XL019 in Adults With Polycythemia VeraPolycythemia VeraNCT00595829Exelixis3
进行中（未招募）
1 期
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung CancerCarcinoma, Non-small-Cell LungNCT06116786Johnson & Johnson Enterprise Innovation Inc.67
终止
1 期
A Study of LY2584702 in Participants With Advanced CancerAdvanced CancerNCT01394003Eli Lilly and Company34
已完成
1 期
A Phase 1 Study of LY2874455 in Participants With Advanced CancerAdvanced CancerNCT01212107Eli Lilly and Company94
进行中（未招募）
1 期
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Multiple MyelomaNCT06604715Janssen Research & Development, LLC17